Patient-reported outcomes in patients with paroxysmal nocturnal hemoglobinuria treated with crovalimab and approved C5 inhibitors in the phase III COMMODORE 2 and 1 studies - Panse, Jens; Han, Bing; Cermak, Jaroslav; Gonzalez Fernandez, Fernando Ataulfo; Gotoh, Akihiko; Kulasekararaj, Austin G; Kyselova, Olena; Sahin, Fahri; Scheinberg, Phillip; Schrezenmeier, Hubert; Straetmans, Nicole; Ueda, Yasutaka; et al. (Annals of hematology, 2025)
Keywords: Crovalimab; Complement C5 inhibitor; Ravulizumab; Patient-reported outcomes; Paroxysmal nocturnal hemoglobinuria; Eculizumab